O-GlcNAcylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation

Area of Science:

• Immunology
• Molecular Biology
• Cancer Research

Background:

• Programmed-death ligand 1 (PD-L1) and its receptor PD-1 are crucial for T cell-mediated anti-tumor immunity.
• Cell surface PD-L1 abundance dictates the success of PD-L1 targeted immune checkpoint blockade therapy.
• Mechanisms regulating PD-L1 cell surface expression remain incompletely understood.

Purpose of the Study:

• To investigate the role of O-linked N-acetylglucosamine (O-GlcNAc) in regulating PD-L1 expression and its impact on anti-tumor immunity.
• To explore O-GlcNAc's influence on the intracellular trafficking and degradation of PD-L1.
• To evaluate strategies for modulating O-GlcNAc pathways to enhance cancer immunotherapy.

Main Methods:

• Investigated the effect of O-GlcNAc modification on PD-L1 intracellular trafficking and lysosomal degradation.
• Utilized O-GlcNAc inhibition to assess its impact on T cell-mediated anti-tumor immunity in vitro and in vivo.
• Developed and tested a peptide inhibitor targeting HGS glycosylation for potential therapeutic application.

Main Results:

• O-GlcNAc modification of hepatocyte growth factor-regulated tyrosine kinase substrate (HGS) inhibits PD-L1 lysosomal degradation.
• O-GlcNAc inhibition enhances T cell-mediated anti-tumor immunity, dependent on HGS glycosylation.
• Combination therapy of O-GlcNAc inhibition and PD-L1 antibody synergistically boosts anti-tumor immune responses.
• A peptide inhibitor of HGS glycosylation reduced PD-L1 expression and improved anti-tumor immunity.

Conclusions:

• O-GlcNAc plays a significant role in tumor immune evasion by regulating PD-L1 degradation.
• Targeting O-GlcNAc glycosylation represents a novel strategy to enhance PD-L1 blockade immunotherapy.
• Modulating HGS glycosylation offers a potential therapeutic approach to overcome tumor immune evasion.